Unlock exclusive insights into the forces reshaping the biopharma industry.
The boundaries between pharma and biotech are becoming less distinct, and there is a growing emphasis on convenience, affordability, and access in drug development.
This article explores the latest trends driving transformation in pharma and biotech, including the emergence of direct-to-patient sales channels that are opening new opportunities. It also examines the increasing prevalence of carve-out and royalty deals within a shifting investment landscape, and discusses why some biotechs are choosing to “go solo” by launching their own products.
Access insights from the industry landscape report: “Pharma v Biotech: New Rules?” and discover:
- Actionable intelligence for navigating pipeline cuts, policy changes, and new financing models
- Strategies to adapt to a modular, consumer-driven biopharma universe
- Inspiration from real-world examples of innovation and resilience
Stay ahead with this guide to the new rules of pharma and biotech.
